MBX Biosciences, Inc.
MBX Biosciences, Inc. (MBX): 11 pipeline candidates · 3 upcoming catalysts · ~63 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
62.8 months
D/E 0.03 · 0% dilution
Lead: Phase 3
11 candidates
3 upcoming, next in ~378d
1 buy · 4 sells (180d)
A transparent, data-derived signal for MBX Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.0B
Cash
$45.2M
Quarterly Burn
$20.2M
Runway
62.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| 200-1600 µg of mbx 2109 once-weekly by | Phase 2 |
| 200-1600 µg of mbx 2109 once-weekly by | Phase 2 |
| 400 µg of mbx 2109 once-weekly by | Phase 2 |
| 400 µg of mbx 2109 once-weekly by | Phase 2 |
| canvuparatide | Phase 2 |
| imapextide | Phase 2 |
| mbx 1416 | Phase 2 |
| mbx 2109 | Phase 2 |
| mbx 4291 | Phase 2 |
| pitolisant | Phase 3 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
156
Total value held
$1.32B
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 3,637,887 | $108.6M |
| wellington management group llp | 3,191,824 | $95.3M |
| vanguard capital management llc | 2,955,184 | $88.2M |
| blackrock, inc. | 2,941,406 | $87.8M |
| fmr llc | 2,936,684 | $87.7M |
| deep track capital, lp | 2,757,569 | $82.3M |
| nvp associates, llc | 2,136,335 | $63.8M |
| woodline partners lp | 1,800,126 | $53.7M |
| polar capital holdings plc | 1,622,186 | $48.4M |
| braidwell lp | 1,492,467 | $44.6M |
Showing top 10 of 156 institutional holders of MBX Biosciences, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in MBX Biosciences, Inc.'s pipeline?
MBX Biosciences, Inc. (MBX) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MBX Biosciences, Inc.'s lead drug candidate?
MBX Biosciences, Inc.'s most advanced tracked candidate is 200-1600 µg of mbx 2109 once-weekly by (Phase 2) for Hypoparathyroidism Who Completed the 12.
What is MBX Biosciences, Inc.'s next catalyst?
MBX Biosciences, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-controlled, Efficacy and Safety Study of Pitolisant Fol" — expected July 1, 2027.
What is MBX Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MBX Biosciences, Inc. has approximately 62.8 months of cash runway.
What is MBX Biosciences, Inc.'s market capitalization?
MBX Biosciences, Inc.'s market capitalization is approximately $2.0B.
Get the full picture on MBX Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.